Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study
It is generally recommended that patients with splanchnic vein thrombosis (SVT) should receive a minimum of 3 months of anticoagulant treatment. However, little information is available on the long-term risk of recurrent thrombotic events. The aim of this study was to evaluate the risk of venous and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/620217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548665737084928 |
|---|---|
| author | Nicoletta Riva Walter Ageno Daniela Poli Sophie Testa Serena Rupoli Rita Santoro Teresa Lerede Antonietta Piana Monica Carpenedo Alberto Nicolini Piera Maria Ferrini Giuliana Martini Catello Mangione Laura Contino Carlo Bonfanti Paolo Gresele Alberto Tosetto |
| author_facet | Nicoletta Riva Walter Ageno Daniela Poli Sophie Testa Serena Rupoli Rita Santoro Teresa Lerede Antonietta Piana Monica Carpenedo Alberto Nicolini Piera Maria Ferrini Giuliana Martini Catello Mangione Laura Contino Carlo Bonfanti Paolo Gresele Alberto Tosetto |
| author_sort | Nicoletta Riva |
| collection | DOAJ |
| description | It is generally recommended that patients with splanchnic vein thrombosis (SVT) should receive a minimum of 3 months of anticoagulant treatment. However, little information is available on the long-term risk of recurrent thrombotic events. The aim of this study was to evaluate the risk of venous and arterial thrombosis after discontinuation of vitamin K antagonist (VKA) in SVT patients. Retrospective information from a cohort of SVT patients treated with VKA and followed by 37 Italian Anticoagulation Clinics, up to June 2013, was collected. Only patients who discontinued VKA and did not receive any other anticoagulant drug were enrolled in this study. Thrombotic events during follow-up were centrally adjudicated. Ninety patients were included: 33 unprovoked SVT, 27 SVT secondary to transient risk factors, and 30 with permanent risk factors. During a median follow-up of 1.6 years, 6 venous and 1 arterial thrombosis were documented, for an incidence of 3.3/100 patient-years (pt-y). The recurrence rate was highest in the first year after VKA discontinuation (8.2/100’pt-y) and in patients with permanent risk factors (10.2/100’pt-y). Liver cirrhosis significantly increased the risk of recurrence. In conclusion, the rate of recurrent vascular complications after SVT is not negligible, at least in some patient subgroups. |
| format | Article |
| id | doaj-art-2c2cafa4090d484a89a1b8f4ea9f0b20 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-2c2cafa4090d484a89a1b8f4ea9f0b202025-02-03T06:13:18ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/620217620217Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort StudyNicoletta Riva0Walter Ageno1Daniela Poli2Sophie Testa3Serena Rupoli4Rita Santoro5Teresa Lerede6Antonietta Piana7Monica Carpenedo8Alberto Nicolini9Piera Maria Ferrini10Giuliana Martini11Catello Mangione12Laura Contino13Carlo Bonfanti14Paolo Gresele15Alberto Tosetto16Department of Clinical and Experimental Medicine, University of Insubria, 21100 Varese, ItalyDepartment of Clinical and Experimental Medicine, University of Insubria, 21100 Varese, ItalyDepartment of Heart and Vessels, Thrombosis Centre, AOU Careggi, 50134 Florence, ItalyHaemostasis and Thrombosis Centre, AO Istituti Ospitalieri, 26100 Cremona, ItalyDivision of Hematology, Haemostasis and Thrombosis Center, AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi, 60020 Ancona, ItalyHemophilia Center, Hemostasis and Thrombosis Unit, Azienda Ospedaliera “Pugliese-Ciaccio”, 88100 Catanzaro, ItalyDepartment of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, 24100 Bergamo, ItalyDepartment of Internal Medicine, Ospedale San Martino, 16100 Genoa, ItalyDepartment of Hematology and Transplant Unit, AO San Gerardo, 20900 Monza, ItalyDepartment of Internal Medicine, Arcispedale Santa Maria Nuova, 42100 Reggio Emilia, ItalyDipartimento Emergenza-Urgenza e Area Medica e Specialistica, AOU Parma, 43100 Parma, ItalySpedali Civili di Brescia, 25100 Brescia, ItalyOspedale di Galatina, 73013 Galatina, ItalyDipartimento Onco-Ematologico e Medicina Specialistica, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, 15100 Alessandria, ItalyDepartment of Transfusion Medicine and Haematology, Carlo Poma Hospital, 46100 Mantua, ItalyDepartment of Internal Medicine, University of Perugia, 06126 Perugia, ItalyDepartment of Hematology, Hemostasis and Thrombosis Center, S. Bortolo Hospital, 36100 Vicenza, ItalyIt is generally recommended that patients with splanchnic vein thrombosis (SVT) should receive a minimum of 3 months of anticoagulant treatment. However, little information is available on the long-term risk of recurrent thrombotic events. The aim of this study was to evaluate the risk of venous and arterial thrombosis after discontinuation of vitamin K antagonist (VKA) in SVT patients. Retrospective information from a cohort of SVT patients treated with VKA and followed by 37 Italian Anticoagulation Clinics, up to June 2013, was collected. Only patients who discontinued VKA and did not receive any other anticoagulant drug were enrolled in this study. Thrombotic events during follow-up were centrally adjudicated. Ninety patients were included: 33 unprovoked SVT, 27 SVT secondary to transient risk factors, and 30 with permanent risk factors. During a median follow-up of 1.6 years, 6 venous and 1 arterial thrombosis were documented, for an incidence of 3.3/100 patient-years (pt-y). The recurrence rate was highest in the first year after VKA discontinuation (8.2/100’pt-y) and in patients with permanent risk factors (10.2/100’pt-y). Liver cirrhosis significantly increased the risk of recurrence. In conclusion, the rate of recurrent vascular complications after SVT is not negligible, at least in some patient subgroups.http://dx.doi.org/10.1155/2015/620217 |
| spellingShingle | Nicoletta Riva Walter Ageno Daniela Poli Sophie Testa Serena Rupoli Rita Santoro Teresa Lerede Antonietta Piana Monica Carpenedo Alberto Nicolini Piera Maria Ferrini Giuliana Martini Catello Mangione Laura Contino Carlo Bonfanti Paolo Gresele Alberto Tosetto Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study Gastroenterology Research and Practice |
| title | Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study |
| title_full | Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study |
| title_fullStr | Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study |
| title_full_unstemmed | Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study |
| title_short | Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study |
| title_sort | recurrent thrombotic events after discontinuation of vitamin k antagonist treatment for splanchnic vein thrombosis a multicenter retrospective cohort study |
| url | http://dx.doi.org/10.1155/2015/620217 |
| work_keys_str_mv | AT nicolettariva recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT walterageno recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT danielapoli recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT sophietesta recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT serenarupoli recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT ritasantoro recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT teresalerede recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT antoniettapiana recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT monicacarpenedo recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT albertonicolini recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT pieramariaferrini recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT giulianamartini recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT catellomangione recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT lauracontino recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT carlobonfanti recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT paologresele recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy AT albertotosetto recurrentthromboticeventsafterdiscontinuationofvitaminkantagonisttreatmentforsplanchnicveinthrombosisamulticenterretrospectivecohortstudy |